AI Accelerates Clinical Diagnostics and Cancer Treatment Worldwide

Artificial intelligence is rapidly moving from experimental research to routine clinical use across the globe. In the United States, the FDA’s breakthrough device pipeline has seen an unprecedented influx of generative‑AI medical tools for imaging, treatment planning, patient monitoring and drug discovery, prompting the agency to develop new regulatory frameworks. China’s massive health system is leading large‑scale deployment of predictive‑analytics platforms that process data from electronic health records, wearables and imaging to anticipate disease and optimise hospital operations. The global AI‑healthcare market, valued at $39 billion in 2025, is projected to exceed $1 trillion by 2034, driven by advances in oncology where multimodal AI platforms combine genomics, pathology and imaging to personalize cancer therapy. Companies such as Sellas Life Sciences argue that AI can shorten drug‑development cycles and improve patient selection for treatments, with its CEO claiming AI will be pivotal in curing cancer. At the same time, new governance solutions like PatientCentricCare.AI’s PCC Safety OS™ aim to embed transparency and accountability into AI workflows to meet emerging regulations such as the EU AI Act. Cautionary perspectives note that AI‑driven diagnostic tests can generate significant false‑positive or false‑negative rates without rigorous validation, as highlighted by a Canadian microbiology expert. Together, these developments illustrate AI’s expanding role in diagnostics, treatment planning, regulatory oversight and patient safety worldwide.